New Launch19 Jun 2025, 09:15 am
Marksans Pharma's UK Subsidiary Gets Marketing Authorization for Oxybutynin Hydrochloride Oral Solution
AI Summary
Marksans Pharma Limited announces that its wholly owned subsidiary, Relonchem Limited, has received Marketing Authorization for the product Oxybutynin hydrochloride 2.5mg/5ml Oral Solution from the UK Medicines & Healthcare Products Regulatory Agency. This approval marks a significant milestone for Marksans Pharma, which is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA.
Key Highlights
- Marksans Pharma's UK subsidiary, Relonchem Limited, receives Marketing Authorization for Oxybutynin hydrochloride 2.5mg/5ml Oral Solution.
- The product is approved by the UK Medicines & Healthcare Products Regulatory Agency.
- Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets.
- The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA.
- This approval marks a significant milestone for Marksans Pharma.